1. Hou R, Wang L, Wu YJ: Predicting ATP-Binding Cassette Transporters Using the Random Forest Method. Frontiers in genetics 2020, 11:156.
2. Matsuo K, Machida H, Frimer M, Marcus JZ, Pejovic T, Roman LD, Wright JD: Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. Gynecol Oncol 2017, 147(3):558-564.
3. Lu KH, Broaddus RR: Endometrial Cancer. N Engl J Med 2020, 383(21):2053-2064.
4. Leslie NR, Downes CP: PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004, 382(Pt 1):1-11.
5. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M et al: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997, 17(2):143-144.
6. Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Fambrini M, Petraglia F, Pillozzi S, Noci I: Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer. Oncol Rep 2019, 41(3):1560-1574.
7. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998, 4(12):3005-3010.
8. Abd El-Maqsoud NM, El-Gelany S: Differential Expression Patterns of PTEN in Cyclic, Hyperplastic and Malignant Endometrium: Its Relation with ER, PR and Clinicopathological Parameters. J Egypt Natl Canc Inst 2009, 21(4):323-331.
9. Li X, Meng Y: Survival analysis of immune-related lncRNA in low-grade glioma. BMC Cancer 2019, 19(1):813.
10. Yu C, Zhang Y: Development and validation of prognostic nomogram for young patients with gastric cancer. Ann Transl Med 2019, 7(22):641.
11. Hou X, Wang D, Zuo J, Li J, Wang T, Guo C, Peng F, Su D, Zhao L, Ye Z et al: Development and validation of a prognostic nomogram for HIV/AIDS patients who underwent antiretroviral therapy: Data from a China population-based cohort. EBioMedicine 2019, 48:414-424.
12. Bi F, Chen Y, Yang Q: Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int 2020, 20:373.
13. Chang YS, Huang HD, Yeh KT, Chang JG: Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. Int J Oncol 2017, 50(5):1778-1784.
14. Dorr C, Janik C, Weg M, Been RA, Bader J, Kang R, Ng B, Foran L, Landman SR, O'Sullivan MG et al: Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor. Mol Cancer Res 2015, 13(8):1238-1247.
15. Wang QA, Yang Y, Liang X: Retraction Note: LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration. J Ovarian Res 2020, 13(1):147.
16. Xin W, Gao X, Zhao S, Zhao P, Yu H, Wu Q, Hua K: LncRNA RP11-395G23.3 suppresses the endometrial cancer progression via regulating microRNA-205-5p/PTEN axis. Am J Transl Res 2020, 12(8):4422-4433.
17. Che Y, Yao Q, Dai S, Luo B, Wang Y: [Study of the mutation and expression of PTEN gene in endometrial carcinoma and epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi 2002, 37(10):608-611.
18. Zhang H, Wang S, Cacalano N, Zhu H, Liu Q, Xie M, Kamrava M, Konecny G, Jin S: Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines. Sci Rep 2019, 9(1):2111.
19. Tao Y, Liang B: PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma. Pathol Res Pract 2020, 216(6):152943.
20. López-Vicente L, Armengol G, Pons B, Coch L, Argelaguet E, Lleonart M, Hernández-Losa J, de Torres I, Ramon y Cajal S: Regulation of replicative and stress-induced senescence by RSK4, which is down-regulated in human tumors. Clin Cancer Res 2009, 15(14):4546-4553.
21. Su X, Li Z, He C, Chen W, Fu X, Yang A: Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget 2016, 7(13):16716-16730.
22. Thakur A, Rahman KW, Wu J, Bollig A, Biliran H, Lin X, Nassar H, Grignon DJ, Sarkar FH, Liao JD: Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res 2007, 5(2):171-181.
23. Thakur A, Xu H, Wang Y, Bollig A, Biliran H, Liao JD: The role of X-linked genes in breast cancer. Breast Cancer Res Treat 2005, 93(2):135-143.
24. Arechavaleta-Velasco F, Zeferino-Toquero M, Estrada-Moscoso I, Imani-Razavi FS, Olivares A, Perez-Juarez CE, Diaz-Cueto L: Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines. Med Oncol 2016, 33(2):11.
25. Rafiee M, Keramati MR, Ayatollahi H, Sadeghian MH, Barzegar M, Asgharzadeh A, Alinejad M: Down-Regulation of Ribosomal S6 kinase RPS6KA6 in Acute Myeloid Leukemia Patients. Cell J 2016, 18(2):159-164.
26. Cai J, Ma H, Huang F, Zhu D, Zhao L, Yang Y, Bi J, Zhang T: Low expression of RSK4 predicts poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol 2014, 7(8):4959-4970.
27. Xu J, Jia Q, Zhang Y, Yuan Y, Xu T, Yu K, Chai J, Wang K, Chen L, Xiao T et al: Prominent roles of ribosomal S6 kinase 4 (RSK4) in cancer. Pathol Res Pract 2021, 219:153374.
28. Zhu J, Li QY, Liu JL, Wei W, Yang HW, Tang W: RSK4 knockdown promotes proliferation, migration and metastasis of human breast adenocarcinoma cells. Oncol Rep 2015, 34(6):3156-3162.
29. Ye Q, Wang X, Jin M, Wang M, Hu Y, Yu S, Yang Y, Yang J, Cai J: Effect of RSK4 on biological characteristics of colorectal cancer. World J Surg Oncol 2018, 16(1):240.
30. Dewdney SB, Rimel BJ, Thaker PH, Thompson DM, Jr., Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow PJ: Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res 2011, 17(8):2120-2129.
31. Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL et al: TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol 2013, 27(4):657-670.
32. Huang C, He C, Ruan P, Zhou R: TSPYL5 activates endoplasmic reticulum stress to inhibit cell proliferation, migration and invasion in colorectal cancer. Oncol Rep 2020, 44(2):449-456.
33. Kim EJ, Lee SY, Kim TR, Choi SI, Cho EW, Kim KC, Kim IG: TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21(WAF1/Cip1) and PTEN/AKT pathway. Biochem Biophys Res Commun 2010, 392(3):448-453.
34. Sun Q, Guo D, Li S, Xu Y, Jiang M, Li Y, Duan H, Zhuo W, Liu W, Zhu S et al: Combining gene expression signature with clinical features for survival stratification of gastric cancer. Genomics 2021, 113(4):2683-2694.
35. Liu Y, Nan F, Lu K, Wang Y, Liu Y, Wei S, Wu R, Wang Y: Identification of key genes in endometrioid endometrial adenocarcinoma via TCGA database. Cancer Biomark 2017, 21(1):11-21.
36. Witek Ł, Janikowski T, Bodzek P, Olejek A, Mazurek U: Expression of tumor suppressor genes related to the cell cycle in endometrial cancer patients. Adv Med Sci 2016, 61(2):317-324.
37. Zheng Y, Pei Y, Yang L, Zeng Z, Wang J, Xie G, Wang L, Yuan J: Upregulated GRB7 promotes proliferation and tumorigenesis of Bladder Cancer via Phospho-AKT Pathway. Int J Biol Sci 2020, 16(16):3221-3230.
38. Vermehren-Schmaedick A, Mhawech-Fauceglia P, Park BS, Pejovic T, Luoh SW: The prognostic significance of GRB7 protein expression and localization in human breast and ovarian cancers. Oncotarget 2020, 11(24):2273-2289.
39. Villalobo A, Berchtold MW: The Role of Calmodulin in Tumor Cell Migration, Invasiveness, and Metastasis. Int J Mol Sci 2020, 21(3).
40. Zúñiga R, Concha G, Cayo A, Cikutović-Molina R, Arevalo B, González W, Catalán MA, Zúñiga L: Withaferin A suppresses breast cancer cell proliferation by inhibition of the two-pore domain potassium (K2P9) channel TASK-3. Biomed Pharmacother 2020, 129:110383.
41. Cikutović-Molina R, Herrada AA, González W, Brown N, Zúñiga L: TASK-3 Gene Knockdown Dampens Invasion and Migration and Promotes Apoptosis in KATO III and MKN-45 Human Gastric Adenocarcinoma Cell Lines. Int J Mol Sci 2019, 20(23).
42. Innamaa A, Jackson L, Asher V, Van Shalkwyk G, Warren A, Hay D, Bali A, Sowter H, Khan R: Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res 2013, 33(4):1401-1408.
43. Ko JH, Gu W, Lim I, Bang H, Ko EA, Zhou T: Ion channel gene expression in lung adenocarcinoma: potential role in prognosis and diagnosis. PLoS One 2014, 9(1):e86569.
44. Niu T, Liu Y, Zhang Y, Fu Q, Liu Z, Wang Z, Fu H, Xu J, Liu K: Increased expression of MUC3A is associated with poor prognosis in localized clear-cell renal cell carcinoma. Oncotarget 2016, 7(31):50017-50026.
45. Zhao W, Xie Y: KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A. Pathol Res Pract 2021, 217:153284.
46. Pandya P, Pasvolsky R, Babichev Y, Braiman A, Witte S, Altman A, Isakov N: PICOT binding to the polycomb group protein, EED, alters H3K27 methylation at the MYT1 PRC2 target gene. Biochem Biophys Res Commun 2019, 509(2):469-475.
47. Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Hart T, Bolouri H et al: Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 2015, 13(11):2425-2439.
48. Le AP, Zhang LL, Liu W, Shi YF: Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells. Oncol Rep 2016, 35(5):2970-2976.
49. Lee NR, Kim DY, Jin H, Meng R, Chae OH, Kim SH, Park BH, Kim SM: Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells. Int J Mol Sci 2021, 22(11).
50. Tsutsumi T, Matsuda R, Morito K, Kawabata K, Yokota M, Nikawadori M, Inoue-Fujiwara M, Kawashima S, Hidaka M, Yamamoto T et al: Identification of human glycerophosphodiesterase 3 as an ecto phospholipase C that converts the G protein-coupled receptor 55 agonist lysophosphatidylinositol to bioactive monoacylglycerols in cultured mammalian cells. Biochim Biophys Acta Mol Cell Biol Lipids 2020, 1865(9):158761.